RecruitingPhase 2NCT05847569

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

Phase II Trial for Evaluation of Alternate Doses and Dosing Schedules of Belantamab Mafodotin in Triple-Class Refractory Multiple Myeloma

Sponsor

Mayo Clinic

Enrollment

62 participants

Start Date

Jan 4, 2024

Study Type

INTERVENTIONAL

Conditions

Refractory Multiple Myeloma Recurrent Multiple Myeloma

Summary

This phase II trial tests alternate doses and dosing schedules of belantamab mafodotin in treating patients with triple-class multiple myeloma that has come back (after a period of improvement) (recurrent) and/or does not respond to treatment (or that has not responded to previous treatment) (refractory). Belantamab mafodotin is a monoclonal antibody, belantamab, linked to a chemotherapy drug, mafodotin. Belantamab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as BCMA receptors, and delivers mafodotin to kill them. This trial may help researchers determine if alternate doses and dosing schedules work better in preventing certain side effects, such as eye toxicity, and treating patients with recurrent or refractory multiple myeloma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing different doses and dosing schedules of a drug called belantamab mafodotin for people with multiple myeloma (a blood cancer) that has stopped responding to three major types of treatment. The goal is to find the most effective and tolerable way to give this drug. **You may be eligible if...** - You are 18 or older - You have a confirmed diagnosis of multiple myeloma - Your cancer has stopped responding to at least three different classes of treatment, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody - You are in reasonably good health **You may NOT be eligible if...** - You have already received belantamab mafodotin (the study drug) - You have significant eye problems, as this drug can affect vision - You have serious organ damage (heart, liver, lungs, or kidneys) - You are pregnant or breastfeeding - You have active infections or brain involvement from myeloma Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.